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A hallmark of all herpesvirus is the ability to exist in either a latent, or lytic, state of replication, enabling the lifelong infection of its host.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) can efficiently establish a latent infection in a variety of cell types in vitro, making it a
valuable model for the study of latency and reactivation. To facilitate the identification of KSHV lytic replication, and allow subsequent
experiments with live cells, a recombinant virus, rKSHV.219, was constructed using JSC-1 cells that expresses the red fluorescent protein
(RFP) from the KSHV lytic PAN promoter, the green fluorescent protein (GFP) from the EF-1a promoter, and with the gene for puromycin
resistance as a selectable marker. rKSHV.219 from JSC-1 cells was used to infect Vero cells for purification of the recombinant virus. Vero
cells were also used for the production of rKSHV.219 at levels of 105–106 infectious units (IU) of virus per milliliter using a combination of
KSHV/RTA expressed from a baculovirus vector, BacK50, and butyrate. Virus produced from Vero cells was used to infect human fibroblasts
(HF), 293, DU145, T24, HaCaT, and HEp-2 cells, and in all cells except 293 cells, only a latent infection was established with GFP
expression, but no RFP expression. In 293 cells, 10–15% of cells showed lytic gene expression. Both primary and immortalized
microvascular endothelial cells (MVEC) were also infected with rKSHV.219, and reduced spontaneous lytic replication was found in
immortalized cells. In all cells used in this study, rKSHV.219 efficiently established latent infections from which the virus could be
reactivated to productive lytic replication. This work also demonstrated strong synergy between KSHV/RTA and butyrate for the activation of
KSHV lytic replication and the production of infectious virus.
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Introduction predominately in a latent state, with periodic reactivationsKaposi’s sarcoma-associated herpesvirus (KSHV) is the
eighth human herpesvirus (HHV-8) to be identified, and as
with all herpesviruses, KSHV can exist in both latent and
lytic replicative states (Jenner et al., 2002; Moore and
Chang, 2001). In the latent state, herpesviruses have
limited gene expression and reside quiescently within the
cell without causing cytopathic effect. With the appropriate
stimulation, the cascade of herpesvirus lytic cycle genes,
consisting of immediate early (IE), early (E), and late (L)
kinetic classes, are expressed resulting in the production of
mature infectious virions. In vivo, KSHV apparently exists0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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and dissemination within the host. Lytic replication has
also been associated with the pathogenesis of KSHV.
Increased virus was detected in PBMC preceding KS
(Whitby et al., 1995), and treatment with gancyclovir,
which inhibits lytic replication, was reported to reduce
the incidence of KS (Martin et al., 1999). In addition,
KSHV encodes many lytic genes that may impact patho-
genesis, such as v-IL6, viral chemokines, and v-GPCR; and
the low percentage of cells with lytic gene expression in
KS lesions may play a role in mediating features such as
angiogenesis, immune infiltration, and the provision of
paracrine functions that are involved with KS (Dourmishev
et al., 2003; Jenner et al., 2002, #1459).
In vivo, many cell types have been identified with KSHV
latent or lytic replication including monocytes, B cells,
endothelial cells, and epithelial cells (Blasig et al., 1997;
Boshoff et al., 1995; Diamond et al., 1998; Dupin et al.,
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and latent replication has also been identified in the three
KSHV-related malignancies, Kaposi’s sarcoma (KS), prima-
ry effusion lymphoma (PEL), and AIDS-related multicentric
Castleman’s disease (MCD). In KS and PEL, essentially all
cells are infected, and greater than 95% of cells contain
latent virus, while in MCD not all cells are KSHV-positive
in the proliferative mass, and there is a higher percentage of
cells with lytic virus than in KS or PEL (Boshoff et al.,
1995; Dupin et al., 1999; Sturzl et al., 1997, 1999).
In vitro, KSHV has been reported to infect more than 20
cell types, including B cells, human fibroblasts (HF),
microvascular endothelial cells (MVEC), 293 cells, human
umbilical vein endothelial cells (HUVEC), DU145, rat
endothelial cells, mouse fibroblasts, and Loukes (Bechtel
et al., 2003; Blackbourn et al., 2000; Friborg et al., 1998;
Mesri et al., 1996; Panyutich et al., 1998; Renne et al., 1998;
Vieira et al., 2001). Of the many cell types infected by
KSHV in vitro, MVEC, which are considered one of the
precursors of KS tumor cells, have proven a valuable
experimental system in that KSHV infection results in most
infected cells harboring latent virus, with a few percentage
of cells undergoing lytic replication with the production of
infectious virus, a situation thought to mimic in vivo
replication (Ciufo et al., 2001; Flore et al., 1998; Lagunoff
et al., 2002; Moses et al., 1999; Panyutich et al., 1998; Poole
et al., 2002). While KSHV can infect many cell types, it
predominately goes latent, and long-term latently infected
cultures have been established (Vieira et al., 2001). The
reasons why KSHV primarily establishes a latent infection
in cell culture are not as yet understood, but this has limited
the generation of significant amounts of virus for experi-
mental studies from any but PEL-derived lines, and has
hampered the production purified recombinant virus.
The activation of lytic replication is a vital aspect of
herpesvirus biology, and while the cellular stimuli that cause
the switch from latent to lytic replication are not well
understood, it is well documented that lytic gene expression
of herpesviruses is initiated by expression of the IE class of
viral proteins that transactivate the expression of the full
complement of viral genes necessary for viral replication
and virion production. KSHV contains a homologue of the
EBV transactivator BRLF1 gene, RTA (replication and
transcription activator), encoded by ORF 50, except for
the first six amino acids which are encoded by an exon 5V of
ORF 50 (Sun et al., 1998). Ectopic expression of the KSHV/
RTA gene can activate lytic gene expression (Lukac et al.,
1998; Sun et al., 1998), and KSHV/RTA can activate the
promoters of KSHV early genes (Chang et al., 2002; Zhang
et al., 1998). While this viral gene can activate lytic
replication, what cellular and viral factors control the
expression and function of KSHV/RTA are only beginning
to be understood. It has been reported that cellular stress,
such as hypoxia, can induce the RTA promoter (Davis et al.,
2001). NF-kB was indicated as inhibiting lytic replication,
and thereby potentially functioning to maintain latency(Brown et al., 2003). A cellular factor, downstream of the
activation of RTA expression, required for lytic replication
has also been identified (Liang and Ganem, 2003). Addi-
tionally, clues to cellular factors that activate KSHV may be
suggested by the fact that KSHV lytic replication can be
induced with chemical agents, such as phorbol esters and
butyrate (Miller et al., 1996; Renne et al., 1996). Phorbol
esters are activators of protein kinase C (PKC), and butyrate
can inhibit histone deacetylase, suggesting that pathways
initiated by PKC, or chromatin state of the viral genome,
may play a role in the natural cellular processes leading to
the promotion of lytic replication.
The alternation between latent and lytic replication is a
vital feature of herpesvirus biology, allowing the permanent
infection of the host. Because KSHV can efficiently estab-
lish a latent infection in many cell types in vitro, it provides
a valuable system for the study of latent replication, as well
as the factors effecting the switch from latency to lytic
replication. To facilitate the study of the switch from latent
to lytic replication, we have developed a recombinant
KSHV that expresses the Ds Red fluorescent protein
(RFP) as a lytic gene, and have used this virus to establish
long-term infected cultures for the examination of latent and
lytic replication in many cell types. The activation of KSHV
lytic replication, and the production of infectious virus by
both KSHV/RTA and chemical reagents have been exam-
ined, and significant synergy in activation by KSHV/RTA
and a histone deacetylase inhibitor was found. In addition,
methods for the purification and production of recombinant
KSHV are presented.Results
Generation of rKSHV.219
To facilitate the identification of KSHV lytic replication,
a recombinant KSHV, rKSHV.219 (Fig. 1A), was con-
structed containing the RFP under the control of the lytic
PAN RNA promoter, along with the GFP gene expressed by
the human elongation factor 1-a promoter, and the pac gene
for resistance to puromycin expressed by the RSV promoter.
This recombinant virus was created by transfecting JSC-1
cells with pQ219, a plasmid which contains a 4.8-kb
segment of KSHV DNA with the RFP/GFP/PURO cassette
inserted between ORF K9 and ORF 57 at a site that
sequence data indicates does not contain a gene. Once
cultures were established under puromycin selection, they
were examined for GFP and RFP expression with, and
without, 12-O-tetradecanoylphorbol-13-acetate (TPA) treat-
ment, and a line showing good induction of RFP with TPA
is shown in Fig. 1B, although it should be noted that there
was wide variation in the expression of RFP following TPA
induction of the different JSC lines generated from the
transfections. The JSC cultures that had grown under
puromycin selection were induced with TPA to produce
Fig. 1. (A) Schematic diagram of the KSHV genome showing an expansion of the 4.8-kb BamHI fragment used to make the recombinant virus, and the
structure and insertion site of the RFP/GFP/PURO construct. The BamHI and HindIII sites of the 4.8-kb fragment are indicated. (B) Photomicrograph of JSC-1
cells transfected with pQ219 and selected with puromycin. Top row: no treatment; bottom row: treated with TPA. Left column: phase; middle column:
fluorescence for GFP; right column: fluorescence for RFP. (C) Photomicrograph of Vero cells infected with rKSHV.219 with the computer-combined images of
fluorescence for GFP (green), DAPI nuclear staining (blue), and Alexa 594-labeled antibody detection of LANA (red). (D) Autoradiograph of the hybridization
analysis of DNA isolated from JSC-1 cells (JSC-1), and from Vero cells infected with rKSHV.219 (KSHV.219). The probes were the 4.8-kb BamHI fragment
(KSHV 4.8) of KSHV used to make the recombinant, or the puromycin resistance gene (Puro). The DNAs were digested with BamHI (B) or HindIII (H) before
electrophoresis. The position of markers in kb is indicated. (E) Ethidium bromide-stained agarose gel following electrophoresis of the PCR products from
amplification of viral DNA from JSC-1 cells, or rKSHV.219, using primers 5V TTGCCAAACCCCATGGCAGAGT and 5V TTGCGGCGAGGTGCAG-
TAATTTC, which flank the insertion site, and amplify a 0.4-kb fragment from JSC-1 DNA, and a 4.2-kb fragment from rKSHV.219. The size in kb of markers
is shown on the left. (F) Northern analysis of total RNA isolated from JSC-1 cells (JSC), uninduced (U) or induced (I) with 15 ng/ml TPA, and Vero cells
containing rKSHV.219 (219) uninduced (U) or induced (I) with RTA and sodium butyrate as described below. The probes were specific for the K9 transcript
(K9) or the ORF 57 transcript (ORF 57).
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multiplicity of infection, and the infected Vero cells were
grown with puromycin selection. Vero cells were chosen
because in previous work with rKSHV.152 (Vieira et al.,
2001), it was found that KSHV efficiently establishes a
latent infection in Vero cells with no production of infec-tious virus (J. Vieira, unpublished observations). Puromy-
cin-resistant Vero cells resulting from the infection with
rKSHV.219 exhibited the coincident expression of GFP and
the latent nuclear antigen (LANA), which was detected by
immunofluorescence and showed the typical punctate nu-
clear staining pattern of latently infected cells, but RFP
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positive Vero colonies resulting from the puromycin selec-
tion were isolated from the cultures and expanded for
further analysis of recombinant virus. Next, the structure
of the recombinant virus was examined, and Fig. 1D shows
the hybridization analysis of total cellular DNA from Vero
cells containing rKSHV.219 and JSC-1 cells with the KSHV
4.8-kb BamHI fragment that was used in constructing the
recombinant virus, and the hybridization analysis of
rKSHV.219 with the puromycin resistance gene. In the
hybridization analysis using the KSHV probe it can be seen
that in the digests of rKSHV.219 there is no wild-type 4.8-
kb BamHI fragment, or 3-kb HindIII fragment detectable,
but fragments unique to the recombinant virus of the size
expected for the addition of the 3.8-kb insert are present in
both the BamHI and HindIII digests of rKSHV.219. The
analysis with the puromycin resistance gene probe identified
the same size fragments as the unique fragments of the
recombinant virus detected by the KSHV probe. This
demonstrated that the recombinant virus, rKSHV.219, is
purified free of wild-type virus, and that the insertion had
recombined at the expected location in the viral genome. As
an additional test that wild-type virus was not present, PCR
reactions were performed with primers flanking the inser-
tion site, and no 0.4-kb band corresponding to wild-type
virus was amplified from rKSHV.219, but a 4.2-kb band
was amplified (Fig. 1E). To confirm that the region of the
insert did not contain a transcribed gene as indicated by
sequence data, and flanking transcripts were not disrupted,
Northern analysis of RNA from JSC-1, and Vero cells
containing rKSHV.219, was carried out, and similar patterns
of transcription with probes for ORFs K9 and 57 were seen
(Fig. 1F).
rKSHV.219 contains the GFP expressed from the elon-
gation factor 1-a (EF 1-a) promoter and there are two points
about the promoter and GFP that are important to the work
to be described below. Firstly, the EF 1-a promoter was
chosen for making recombinant viruses because it is a
strong cellular promoter without an identified strong en-
hancer, which if present could impact the expression of
nearby viral genes. However, needs to be noted that while
the EF 1-a promoter expressed GFP in 15 different cell
types that have been infected by rKSHV.219, there can be
variation in the level and percentage of infected cells that
express GFP. In some cell types, essentially all infected cells
express GFP, as illustrated by 293 cells in Fig. 2A, where 2
days postinfection the expression of GFP and the detection
of LANA by immunofluorescence are coincident. In other
cell types, not all infected cells express detectable levels of
GFP, as demonstrated by GFP and LANA detection in
infected MVEC (Fig. 2B), where LANA-positive nuclei
(red) are present that are not associated with GFP-positive
cells. The silencing of the EF 1-a promoter has also been
observed in some cells, such as HF or MVEC, where in
cultures with mostly GFP-positive cells that had been
passaged in the presence of puromycin, there were are alsocells that did not express detectable levels of GFP unless
they were treated with inducers of gene expression such as
sodium butyrate, or activators of lytic gene replication such
as KSHV/RTA, or infection with HCMV (J. Vieira, unpub-
lished observations). Secondly, in many experiments de-
scribed below, the expression of GFP by rKSHV.219
infection of 293 cells was used as an assay for the presence
of infectious virus. 293 cells were chosen for this assay
because as demonstrated in Fig. 2A, 293 cells exhibit easily
detectable levels of GFP expression in all infected cells 2
days postinfection. In addition to the fact that the coincident
expression of GFP and LANA demonstrate that the presence
of GFP is due to viral infection, two other controls were
carried out that demonstrate the GFP detected is due to gene
expression resulting from viral infection. Firstly, that GFP
expression requires gene expression is indicated by the fact
that in 293 cultures infected with rKSHV.219 there are no
GFP-positive cells 4 h postinfection, but GFP-positive cells
are evident 1 day postinfection. Secondly, in the experi-
ments described below using infectious rKSHV.219, virus
was harvested from cell-free media, and the cells were not
sonicated, so there was very little GFP or RFP present in
virus stocks. However, we have examined the incubation of
293 cells with an inoculum containing a much greater
amount of GFP than would be present in rKSHV.219
preparations, but that contained no infectious virus. This
inoculum was prepared by sonicating Vero cells containing
latent rKSHV.219 (which express GFP but do not produce
infectious virus), and after removing the cellular debris by
centrifugation, the supernatant was used to inoculate 293
cells. At 1 and 2 days post inoculation with this material, no
GFP-positive cells were observed (data not shown).
Activation of KSHV lytic replication in Vero cells
It had previously been found in work with rKSHV.152
(Vieira et al., 2001) that ectopic expression of KSHV/RTA
from transfected plasmid, or expression by infection with a
recombinant Baculovirus (BacK50) expressing KSHV/RTA
from the HCMV major immediate promoter, could activate
latent KSHV in Vero cells to a productive lytic replication,
and that sodium butyrate could activate lytic KSHV gene
expression alone, and also significantly augmented virus
production by KSHV/RTA (J. Vieira, unpublished observa-
tions). In Fig. 3, the activation of lytic gene expression in
Vero cells containing rKSHV.219 by the treatment with
sodium butyrate, the expression of RTA by infection with
BacK50, or the combination of RTA and sodium butyrate, is
demonstrated by RFP expression, and the antibody detec-
tion of the early lytic ORF 59 protein with MAb 11D1
(Chan et al., 1998), or the antibody detection of the late lytic
K8.1 protein with MAb A4 (Zhu et al., 1999). This
experiment demonstrated that the lytic antigens were only
found in cells that are RFP-positive and not in cells only
expressing GFP. In addition, both ORF 59 and K8.1 anti-
gens were present in cells activated by all three conditions,
Fig. 2. Detection of GFP and LANA in cells infected by rKSHV.219. (A1) 293 cells, 2 days postinfection with rKSHV.219, showing GFP expression (green),
LANA detection by immunofluorescence with Alexa 633 (red), and DAPI staining of nuclei (blue). (A2) Image of the immunofluorescence detection of LANA
in 293 cells, alone. (B1) MVEC, 5 days postinfection with rKSHV.219 showing GFP expression (green), LANA detection by immunofluorescence with Alexa
594 (red), and DAPI staining of nuclei (blue). (B2) Image of the immunofluorescence detection of LANA in MVEC alone. The green, red, and blue channels
were imaged separately and combined.
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with butyrate alone, and the greatest amount of cells
expressing lytic antigens present in cultures activated byFig. 3. The six panels are photomicrographs of Vero cells containing rKSHV.219 s
2 days post induction. The induction conditions for the different panels were the fo
sodium butyrate. KSHV proteins were detected using immunofluorescence with
right, RFP; lower left, immunofluorescence for KSHV protein; lower right, overlay
59 is in panels 1–3, and the detection of OFK K8.1 is in panels 4–6.both sodium butyrate and KSHV/RTA. There was no
induction of RFP expression by infection with a Baculovirus
vector not carrying the KSHV/RTA gene (data not shown).howing the detection of GFP, RFP, and ORF 59 protein or ORF 8.1 protein
llowing: 1 and 4, sodium butyrate; 2 and 5, BacK50; 3 and 6, BacK50 and
Alexa 388 (blue). The quadrants of each panel are: upper left, GFP; upper
of RFP and immunofluorescence for KSHV protein. The detection of ORF
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with the different induction conditions it was of interest to
determine if this was predictive of differences in the
amount of infectious virus being produced. To investigate
this, the GFP gene carried by rKSHV.219 was utilized for
the detection of infectious virus by infecting 293 cells
with cell-free culture supernatants from cultures with
rKSHV.219, and counting GFP-positive cells 2 days
postinfection of the 293 cells. The number of GFP-
positive cells produced per milliliter of media was used
as the number of infectious units (IU) of KSHV per
milliliter. The amount of infectious virus produced from
Vero cells containing rKSHV.219 uninduced, and 3 days
post induction with sodium butyrate, RTA expressed by
BacK50, or BacK50 in combination with sodium butyrate,
was determined by titering cell-free media from the
cultures on 293 cells and counting GFP-positive cells.
Fig. 4A shows the IU produced by the different activation
processes and demonstrates that while no virus is pro-
duced by uninduced cultures, all three activation condi-
tions resulted in the production of infectious rKSHV.219.
Moreover, in agreement with the number of cells detected
expressing lytic proteins, sodium butyrate alone produced
the least amount of infectious virus, with the combination
of RTA and butyrate resulting in the highest level of virus
production. To assess that the action of sodium butyrate in
augmenting KSHV production was not specific to bacu-
lovirus expression of KSHV/RTA, Vero cells with
rKSHV.219 were transfected with a plasmid expressing
KSHV/RTA from the HCMV IE promoter, and then
cultured minus or plus sodium butyrate, and as with
BacK50, sodium butyrate increased virus production
(Fig. 4A). While RFP expression was visible 1 day post
induction, it did not indicate when infectious virus is
produced. To determine the timing of the production of
infectious KSHV from Vero cells, a time course of
rKSHV.219 production from Vero cells activated withFig. 4. (A) The production of infectious rKSHV.219 from latently infected Vero cel
induction conditions included sodium butyrate (SB), infection with BacK50 (BacK
HCMV IE promoter as indicated beneath the graph. The graph represents the
supernatants from the cultures on 293 cells and counting GFP-positive cells. (B) Th
cells following induction with BacK50 and sodium butyrate (1 mM) at the timeRTA and sodium butyrate was carried out, and it was
found that infectious virus was produced as early as 36 h
post induction (Fig. 4B).
Because the blocking of histone deacetylases (HDACs) is
considered the major mechanism by which sodium butyrate
activates gene expression, another inhibitor of HDACs,
trichostatin A (TsA), was also tested for its ability to activate
KSHV. Treatment with TsA led to RFP expression and the
production of infectious KSHV (Fig. 5). It was noted that
TsA was more toxic to Vero cells than sodium butyrate,
which may have contributed to the narrow range for TsA
induction, below 0.05 Am gave very little induction, and
above 0.1 Am had significant toxicity. While the level of
infectious virus was lower than that produced by sodium
butyrate induction, the TsA data supported the role of
histone state in the maintenance of latency.
The experiments with butyrate and TsA indicated an
important role of histone acetylation, which can be closely
linked with DNA methylation (Bestor, 1998), in the activa-
tion of KSHV. In addition, previously published work
indicated that DNA methylation plays a role in controlling
expression from the KSHV/RTA promoter, and that the
KSHV/RTA promoter is hypomethylated following TPA
induction of KSHV in a PEL line (Chen et al., 2001). For
these reasons, we next examined an inhibitor of DNA
methylation, 5-azacytidine, for the activation of rKSHV.219.
Vero cells containing latent KSHV were treated with 5-
azacytidine and assessed for RFP expression and virus
production. 5-Azacytidine treatment induced RFP expres-
sion, although there was little CPE, and infectious virus was
not detected (Fig. 5). While compounds effecting HDACs
and DNA methylation could activate KSHV in Vero cells,
TPA did not (data not shown).
The previous experiments showed that KSHV/RTA
could activate productive KSHV lytic replication in Vero
cells, with sodium butyrate considerably increasing virus
production; therefore, Vero cells were used as a convenientls, with no activation, or 3 days post activation of lytic gene expression. The
50), or a plasmid construct (pCMV-RTA) expressing KSHV/RTA from the
infectious units of rKSHV.219 as were determined by titering cell-free
e timing of production of infectious rKSHV.219 from latently infected Vero
points indicated beneath the graph.
Fig. 5. (A) Photomicrograph of Vero cells containing rKSHV.219 induced with TsA or 5-AzaC at the indicated concentrations showing images of phase, GFP
fluorescence, and RFP fluorescence 2 days post induction. (B) Graph of the detection of infectious units of KSHV from cultures induced by TsA or 5-AzaC
3 days post activation by titering cell-free culture supernatants on 293 cells.
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Vero cells with rKSHV.219 in 150 cm2 flasks were used for
the production of viral stocks, and photomicrographs of
cells, pre-activation and 2 days post-activation, are shown in
Fig. 6A. While the uninduced cultures exhibited normal
morphology, and no RFP expression, the induced culture
had RFP expression plus significant CPE. IU of rKSHV.219
were determined by the titering of media from induced
cultures on 293 cells and counting GFP-positive cells 2 days
postinfection, and the activation of rKSHV.219 containingFig. 6. (A) Photomicrograph of Vero cells infected with rKSHV.219 pre-activation (
butyrate showing images of phase, GFP fluorescence, and RFP fluorescence, as in
an example of the titering of rKSHV.219 on 293 cells showing GFP expression 2 d
containing rKSHV.219 activated with BacK50 and butyrate. The titer of the rKSHVero cells with BacK50 and sodium butyrate in 150 cm2
flask with 25 ml of media resulted in the production of 105–
106 infectious units per milliliter of rKSHV.219. An exam-
ple of a titering procedure is shown in Fig. 6B with a
photomicrograph of 293 cells plated in a 3.83 cm2 well
inoculated with 0.025 ml of cell free media from the induced
Vero cells containing rKSHV.219 with a titer of approxi-
mately 7  105 IU of virus.
rKSHV.219 produced from Vero cells was used to infect
293 cells, human fibroblasts, microvascular endothelialUntreated), and 2 days post-activation (Activated) with BacK50 and sodium
dicated. (B) Photomicrographs of the phase image and GFP fluorescence of
ays postinfection with 0.025 ml of cell free media harvested from Vero cells
V.219 was approximately 7  105 IU/ml.
Fig. 7. (A) HF infected with rKSHV.219. Photomicrographs of GFP and
RFP fluorescence in untreated cells (top row), and cells 2 days post
activation with BacK50 (middle row), or 2 days post activation with
BacK50 plus sodium butyrate (bottom row). (B) Infectious units of
rKSHV.219 produced by latently infected HF without and treatment, or
treated with sodium butyrate (SB) or infected by BacK50 (BacK50), as
indicated below the graph determined 3 days post activation.
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could be infected as indicated by GFP expression, and these
cultures were then evaluated for production of infectious
KSHV, without or with activation as presented below.
Human fibroblasts
It was previously demonstrated that KSHV establishes a
latent infection in HF as demonstrated by viral protein
expression and gardella gel analysis (Vieira et al., 2001).
The infection of HF with rKSHV.219 resulted in GFP
expression, but not RFP expression, although it should be
noted that an occasional RFP-positive cell (<100000) was
seen in HF cultures. HF carrying latent rKSHV.219 were
tested for virus activation by KSHV/RTA without, or with,
sodium butyrate. While RFP was not expressed in HF, the
infection of HF containing rKSHV.219 by BacK50 induced
significant RFP expression (Fig. 7A) and the production of
infectious virus (Fig 7B). The combination of BacK50 and
sodium butyrate led to RFP expression, more CPE than
BacK50 alone (Fig. 7A), and resulted in a significant
increase in the level of virus produced as compared to
BacK50 alone (Fig. 7B). As with Vero cells, TPA did not
activate virus (data not shown). These results demonstrated
that fibroblasts with an established latent infection are fully
permissive for the complete lytic replication cycle of KSHV
following activation by KSHV/RTA in agreement with
previous work (Bechtel et al., 2003; Vieira et al., 2001),
and again showed the impact of butyrate on increasing the
level of infectious KSHV.
293 cells
In 293 cells infected with rKSHV.219, while no GFP was
detected on the day of infection, GFP expression was
evident as early as 1 day postinfection, and high-level
GFP expression was evident 2 days postinfection (Fig.
8A), but RFP expression was not (although not present in
Fig. 8A, it should be noted that occasional RFP-positive
cells could be present at 2 days postinfection). In long-term
rKSHV.219-infected cultures, which were established with
puromycin selection, a relatively stable mixture of cells
expressing only GFP, and cells expressing both GFP and
RFP, were present 1 month postinfection (Fig. 8B), indicat-
ing some level of lytic gene expression. Although the cells
shown in Fig. 8B were grown with puromycin, the induction
of RFP expression occurred even without antibiotic selec-
tion (data not shown). To confirm that the RFP expression
indeed signified lytic gene expression, 293 cells infected
with rKSHV.219 were examined for ORF 59 expression
using monoclonal antibody 11D1 (Chan et al., 1998), and
ORF 59 was present in cells expressing RFP (Fig. 8C).
Long-term rKSHV.219-infected 293 cells were examined
for the production of infectious KSHV without any treat-
ment, or treated with BacK50 or sodium butyrate by titering
culture supernatants on 293 cells and counting GFP-positive
cells (Fig. 8C). Even with the high level of spontaneous lytic
activation in KSHV-infected 293 cultures, there were onlylow levels of virus produced. Increased virus production
was seen with activation by sodium butyrate or KSHV/RTA,
with the highest levels of infectious virus produced with
both, but the levels were still lower than Vero cells or
fibroblasts. Treatment of rKSHV.219-infected 293 cells with
phorbol esters, or 5-azacytidine increased the level of lytic
gene expression as indicated by RFP expression, and there
was approximately a 3-fold increase in virus production
with TPA, but not a detectable increase in virus yield with 5-
azacytidine (data not shown).
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Microvascular endothelial cells have proven a valuable
cell system for the study of KSHV, although because of the
limited life span of primary MVEC, immortalized MVEC
have been developed and used for KSHV experimentation
(Lagunoff et al., 2002; Moses et al., 1999). While immor-
talized cells are of significant convenience, the comparison
of primary cells with immortalized cells derived from them,for the growth of KSHV, has not been examined. As a
preliminary examination of this question, pooled MVEC
were immortalized with hTert, or with hTert combined with
papilloma virus E7 (Halbert et al., 1991; Kiyono et al.,
1998). Both the hTert and the hTert/E7 cell lines continued
to proliferate beyond the life span of the primary cells.
During the passage of these lines, the hTert line suffered a
minor crisis of slowed growth, while the hTert/E7 line did
not, similar to that reported for keratinocytes (Dickson et al.,
2000). The primary MVEC, and the immortalized lines were
infected with rKSHV.219, and all three lines were efficiently
infected with the majority of cells becoming GFP-positive.
The examination of the three cultures for RFP expression
revealed that in the primary cells there were frequent RFP-
positive cells, including groups of RFP-positive cells; while
in the immortalized lines, there were far fewer RFP-positive
cells, which were most often single cells. Examples of GFP
and RFP expression in primary, and hTert/E7 immortalized
cells, are shown in Fig. 9A. The primary and immortalized
MVEC were then tested for the production of infectious
KSHV without activation. Because with the same cells,
noticeable well to well variation in RFP expression was
observed, virus titers were determined from five wells of
culture initiated at the same time and split 1:2 once (Fig.
9B). As predicted by the level of RFP expression, primary
cells produced infectious virus at higher levels than the
immortalized cell lines. To test if the reduced virus produc-
tion by immortalized cell lines was simply due to a lack of
spontaneous activation and not an inability to produce virus,
primary and immortalized KSHV-infected cultures were
treated with HCMV, TPA, or BacK50 and butyrate to
activate KSHV lytic replication. The activation of KSHV
lytic gene expression in primary and hTert/E7 cells by
BacK50 and butyrate, as indicated by RFP expression, is
shown in Fig. 9C, demonstrating a high percentage of
activation. The level of infectious virus produced by unac-
tivated and activated cultures was determined 3 days post
activation (Fig. 9D). In these experiments, it was found that
KSHV was activated from primary or immortalized cells by
HCMV, or BacK50/butyrate, to similar levels of infectious
virus. While treatment with TPA increased virus yield by
more then 10-fold in immortalized cells, the yield of virus
was below the amount of virus produced by TPA-induced
primary cells.Fig. 8. (A) Photomicrographs of 293 cells infected with rKSHV.219 2 days
postinfections showing phase, GFP fluorescence, and RFP fluorescence.
(B) Long-term rKSHV.219-infected culture of 293 cells showing the
overlay of GFP and RFP fluorescence (left panel), and RFP fluorescence
(right panel). (C) GFP, RFP and ORF 59 protein expression in 293 cells, as
indicated above each image. The ORF 59 protein was detected with
monoclonal antibody 11D1 by immunofluorescence with Alexa 388 (blue)
as the fluorescent marker. The lower right panel is the computer-generated
overlay of RFP and the immunofluorescence for the ORF 59 protein. (D)
Graph of the production of infectious rKSHV.219 from long-term infected
293 cells, without activation, or 3 days post activation by sodium butyrate
(SB) or BacK50 (BacK50), as indicated beneath the graph.
Fig. 10. (A) Photomicrographs of long-term rKSHV.219-infected cultures
of HEp-2, HaCaT, DU145, and T24 cells 2 days posttreatment with BacK50
and sodium butyrate (3 mM) showing: top row, phase image; middle row,
GFP fluorescence; and bottom row, RFP fluorescence. (B) Graph of
infectious units of rKSHV.219 produced by the indicated cell types 3 days
post treatment with BacK50 and butyrate.
Fig. 9. (A) Photomicrographs of primary and hTert/E7 immortalized MVEC
infected with rKSHV.219 showing phase, and GFP and RFP expression. (B)
Production of infectious units of rKSHV.219 by primary and immortalized
MVEC cultures with no activation. The n refers to five separate 3.83 cm2
wells, and the range is the range of titers of IU from the separate wells. (C)
Photomicrographs of primary and hTert/E7 immortalized cells infected with
rKSHV.219 and activated with BacK50 and butyrate (3 mM) showing phase,
GFP fluorescence, and RFP fluorescence. (D) Graph of infectious units of
rKSHV.219 produced by primary, hTert immortalized, and hTert/E7
immortalized MVEC without activation ( ), or activated by HCMV
infection (HCMV), treatment with 15 ng/ml TPA (TPA), or infection with
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To determine if other cell lines supporting only latent
replication of KSHV were proficient for the production of
infectious virus following activation, four additional cells
were tested. Latent infection of the bladder carcinoma cell
BacK50 in combination with 3 mM butyrate (BacK50/butyrate).line T24, and the prostate carcinoma line DU145 by KSHV
was previously documented by gardella gel analysis (Vieira
et al., 2001) In this work, rKSHV.219 was used to infect
T24, DU145, HaCaT, a spontaneously immortalized epithe-
lial cell line, and HEp-2 cells, derived from a larynx
carcinoma. rKSHV.219 efficiently infected all four cell
types and latently infected lines were established. No virus
production was detected from any of the four, and all
maintained normal cell morphology, although occasional
RFP-positive cells were observed in T24 and Hep2 cells. To
determine if these cells were permissive for virus produc-
tion, they were treated with KSHV/RTA, in combination
with sodium butyrate, to activate lytic replication. In Fig.
10A, photomicrographs of the four cell types 2 days post
induction are shown, and all cell types expressed RFP,
indicative of lytic gene expression. To determine if infec-
tious virus was produced, virus in cell-free media was
titered on 293 cells and the level of infectious units was
determined (Fig. 10B). While the yield of virus was lower
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virus.Discussion
In this report, we describe a recombinant virus
rKSHV.219 that expresses the RFP as a lytic gene, enabling
the identification of lytic gene expression without the
destruction of the culture as is needed for the antibody
detection of lytic proteins. This virus also carries the GFP
that is expressed in the majority of latently infected cells,
allowing the identification of infected cells whether lytic or
latent, and the gene for puromycin resistance that enables
the selection of infected cells. In rKSHV.219, the RFP
protein is expressed from the strong lytic PAN promoter
(Sun et al., 1996; Zhong et al., 1996) that can be directly
activated by KSHV/RTA (Chang et al., 2002; Song et al.,
2001). The expression of RFP from the PAN promoter was
found to be a sensitive assay for lytic gene expression, in
that RFP was not seen in latently infected cells, all cells that
expressed lytic antigens also expressed RFP, and infectious
rKSHV.219 was only produced in cultures exhibiting RFP
expression. While only RFP- positive cells were positive
for antibody detection of lytic proteins, there were RFP-
positive cells that did not stain for the ORF 59 or ORF 8.1
proteins. This could be due to the proteins being present, but
at levels below detection, or that there are different levels of
lytic activation for KSHV as previously indicated by a
greater number of cells expressing early than late genes
(Moses et al., 1999). Because the PAN promoter can be
directly activated by RTA, it may be present in all cells
responsive to RTA activation, while some lytic genes may
require other viral or cellular functions, such as DNA
replication for the expression of ORF 8.1, that may vary
from cell to cell and impact lytic gene expression.
A novel aspect of this work was the use of Vero cells for
the purification and production of recombinant KSHV at
titers of 105–106 infectious units per milliliter. The produc-
tion of infectious rKSHV.219 was carried out by propagat-
ing latent virus in Vero cells, and then inducing lytic
replication. Virus isolated from Vero cells efficiently
infected more than a dozen cell types, and could grow
lytically in MVEC, and produce infectious virus that could
be passaged to other cell lines, as well as back to Vero cells.
Vero cells provide a convenient cell type for the production
of KSHV that has robust growth characteristics and can be
efficiently transfected. Therefore, Vero cells containing
rKSHV.219 provide a relatively straightforward system for
the generation of recombinant virus by using rKSHV.219 as
the parental virus and the use of a second selectable marker
for the disruption of a viral gene, or the introduction of other
genetic modifications (J. Vieira, unpublished data). This
system should also prove useful for the production of
recombinant KSHV made in Bacmid vectors (Delecluse et
al., 2001; Zhou et al., 2002), where such constructs can betransfected into Vero cells, selected for as latently growing
virus and then activated for the production of recombinant
virus for further experiments.
Since the identification of the KSHV RTA gene as being
capable of transactivating lytic gene transcription (Sun et al.,
1998), numerous studies have confirmed its vital role in the
activation of latent to lytic replication (Gradoville et al.,
2000; Lukac et al., 1998; Lukac et al., 1999). Previously,
ectopic expression of KSHV/RTA has been achieved using
plasmid transfection (Gradoville et al., 2000; Lukac et al.,
1998; Sun et al., 1998), Tet inducible systems (Nakamura et
al., 2003), Adenovirus vectors (Bechtel et al., 2003), and in
this study we used a Baculovirus, BacK50, expressing the
KSHV/RTA from the HCMV IE promoter. BacK50 pro-
vides a convenient system for the production of a high titer
viral vector expressing KSHV/RTA that can infect a very
wide variety of mammalian cells, with very minimal impact
(Kost and Condreay, 2002). In the present study, we found
that ectopic expression of KSHV/RTA from BacK50 was
able to activate lytic replication from established latently
infected cultures and result in the production of infectious
virus from the cells used in this study, in agreement with the
many previous studies showing that KSHV/RTA is an
effective activator of KSHV lytic replication. The demon-
stration that KSHV/RTA has the ability to activate virus
from a variety of long-term latently infected cultures indi-
cates that the control of RTA expression is a crucial aspect
of the establishment and maintenance of latency.
In this study, we also found that sodium butyrate was able
to activate the lytic gene expression of KSHV, as well as
significantly augment the level of infectious virus produced
by KSHV/RTA activation. The ability of butyrate to inhibit
HDACs, and thereby increase the level of histone acetylation
that is correlated with transcriptional activity, is considered
the mechanism by which it can activate gene expression
(Kruh, 1982); and butyrate has been shown to activate KSHV
lytic gene expression in PEL lines (Miller et al., 1996; Yu et
al., 1999). The fact that butyrate, alone, can result in the
production of infectious virus indicates the important role of
chromatin state on the maintenance of latency, and its role in
controlling lytic transcriptional activity of herpesviruses.
While the addition of butyrate increased the yield of KSHV
producedwith RTA activation, the impact of butyrate on virus
activation in conjunction with the ectopic expression of
KSHV/RTA is difficult to fully assess because butyrate can
also increase the expression of genes introduced by baculo-
virus infection, or transfection. It is likely though, that in
addition to increasing ectopic expression of KSHV/RTA,
butyrate treatment induces modifications of the chromatin
structure of the viral genome that results in enhanced activa-
tion by KSHV/RTA. In support of a role for butyrate in lytic
activation, besides increasing ectopic RTA expression, was
that a 20-fold increase in the amounts of BacK50 or trans-
fected plasmid could not compensate for the absence of
butyrate in viral yield (J. Vieira, unpublished data). The
interaction of KSHV/RTA with both HDAC (a transcription
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hancer) was reported, and because these two cellular proteins
have opposite effects on transcription, it was suggested that
the balance between these two proteins may play a role in
controlling latency (Gwack et al., 2001). The inhibition of
HDACs by butyrate may therefore shift the balance toward
the action of CREB-binding protein, and lead to a better
activation of KSHV lytic genes in combination with KSHV/
RTA. It must also be considered that butyrate may induce the
expression of a cellular gene that increases virus production.
For the study of KSHV replication, MVEC have proven a
valuable cell system that provides both latent replication, as
well as a low level of lytic replication with the production of
infectious virus, and have been important to a variety of
KSHV studies (Ciufo et al., 2001; Flore et al., 1998; Lagun-
off et al., 2002; Moses et al., 2002; Panyutich et al., 1998).
The limited life span of primary MVEC have resulted in the
use of immortalized MVEC for KSHV research (Lagunoff et
al., 2002; Moses et al., 1999). Because MVEC, and immor-
talized lines, are an attractive culture system for the use of
rKSHV.219 in the study of factors activating lytic replica-
tion, we wanted to compare the replication of KSHV in
primary cells and immortalized cells from the same source, a
comparison that has not been done. Our examination of
primary MVEC, and MVEC immortalized with hTert, or
hTert and papiloma virus E7 gene found that the immortal-
ized cells had spontaneous lytic growth much below that of
the primary cells. While it is not known what features of
immortalized cells results in the tighter maintenance of
latency, it was found that when activated by KSHV/RTA,
HCMV, or TPA, the immortalized cells could produce levels
of infectious virus about the same as similarly induced
primary cells, indicating there are no blocks to lytic replica-
tion once it is initiated. While much work is needed on
understanding the differences between primary and immor-
talized cells, these preliminary experiments do indicate there
can be differences that should be considered in the use of
immortalized cells. It is also very likely that there will be
differences between immortalized lines, and some may retain
a greater degree of primary phenotype than others.
Although the production of infectious virus from unac-
tivated cultures was only detected from 293 cells and
MVEC, all cells presented here could produce virus when
activated, and levels of infectious virus over 106 infectious
units per milliliter have been achieved from Vero cells. This
level of virus still only represents a few infectious units per
cell, and if this is because only a low percentage of cells
produce a high amount of virus, or because each cell only
produces a few infectious virions, is yet to be determined.
These studies have demonstrated that the RFP expressed
from the PAN promoter is a sensitive assay for KSHV lytic
gene expression in living cells, and the easy identification of
latent and lytic replication in living cells afforded by
rKSHV.219 will facilitate the investigation of the questions
involved in the reactivation of herpesviruses. In agreement
with many previous studies, we also found that the KSHV/RTA is capable of activating lytic gene expression (Bechtel
et al., 2003; Gradoville et al., 2000; Lukac et al., 1998;
Nakamura et al., 2003; Sun et al., 1998; ). That KSHV/RTA
could activate virus from a variety of established long-term
latent cultures indicates that the control of the KSHV/RTA
promoter plays a critical role in the propensity of KSHV to
establish a latent infection in vitro, and most likely in vivo.
The impact of sodium butyrate on the activation of KSHV
indicates that chromatin state also plays an important role in
maintaining latency, and its significant synergy with RTA
indicates that both are important components in the produc-
tion of infectious virus. A better understanding of the factors
influencing both the expression of RTA, and the state of
viral associated chromatin, will provide important insight
into the switch from latent to lytic replication, and the
combined use of KSHV/RTA and butyrate will aid in the
production of recombinant virus for a variety of studies.Material and methods
Cells
Fibroblasts were of human foreskin origin. T24, HaCaT,
Vero, Hep2, and DU145 cells were obtained from the
American Type Culture Collection. HF, T24, HaCaT, Vero,
Hep2, and DU145 were maintained in Dulbecco’s modified
Eagle’s medium (DMEM;Gibco BRL, Rockville, MD, USA)
supplemented with 10% fetal bovine serum (FBS), 100 Ag/ml
streptomycin, 100 U/ml penicillin, and 2 mM L-glutamine
in a humidified 5% CO2 37 jC incubator. JSC-1 cells were
obtained from J.S. Cannon andR.FAmbinder, Johns Hopkins
University School of Medicine, Baltimore, MD, USA, and
cultured in RPMI supplemented with 10% FBS 0.1 mg
streptomycin, 100 U penicillin, and 2 mM L-glutamine.
Microvascular endothelial cells were from Clonetics (San
Diego, CA, USA) and cultured in EGM-2 media from
Clonetics as recommended. MVEC were immortalized with
retroviral vectors expressing hTert or Papiloma E7 obtained
from J.K. MacDougall, FHCRC, Seattle, WA, as previously
described (Halbert et al., 1991; Kiyono et al., 1998).
Construction of recombinant KSHV
JSC-1 cells were used as the source for KSHV. For the
construction of recombinant virus, a 4.8-kb BamHI frag-
ment (positions 81046–85820 of the published sequence;
Russo et al., 1996) was isolated from the cosmid Z8 (Russo
et al., 1996) and cloned into pUC21 to create pQ131. At the
DraIII site (position 83710 of the KSHV sequence) present
in the BamHI fragment, after the ends were made blunt with
T4 DNA polymerase and dNTPs, a blunt-ended DNA
fragment containing the enhanced green fluorescent protein
(GFP) (Clontech, Palo Alto, CA, USA) gene expressed by
the elongation factor 1-a promoter, the puromycin N-ace-
tyltransferase (pac) gene expressed by the RSV promoter,
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expressed by the PAN RNA promoter (position 28520–
28690) was inserted to create pQ219. pQ219 was used to
electroporate JSC-1 cells as previously described (Vieira et
al., 2001), and each of the 16 transfections was plated to
three wells of a 12-well plate, resulting in 48 cultures. Three
days post electroporation, the cells were grown with 0.5 Ag/
ml puromycin (Calbiochem, San Diego, CA, USA) to select
for recombinants. The cells in 38 of the 48 wells grew under
puromycin selection and were expanded to six-well plates.
For the production of virus from the 38 cultures, cells were
grown to a density of 5  105 cells/ml and induced with
15 ng/ml TPA and grown for 4 days. To harvest virus, cells
were pelleted at 300  g for 10 min, passed through a 0.8-
AM filter, and the supernatant was used as virus inoculum to
infect Vero cells. As judged by GFP expression, the infec-
tion of Vero cells was typically at a multiplicity of infection
(moi) of less than 0.001. Two days post inoculation, the
infected Vero cells were grown with 5 Ag/ml puromycin. It
should be noted that even at 5 Ag/ml puromycin, spontane-
ous Vero mutants arose that were resistant to puromycin.
It should be noted that even at 5 Ag/ml puromycin
spontaneous Vero mutants could arise that were resistant
to puromycin. This could cause the occurrence in cultures of
Vero cells with rKSHV.219 of cells that had gained puro-
mycin resistance and had lost rKSHV.219 by segregation
(and were therefore not GFP-positive). The occurrence of
such cells could be reduced, but not eliminated, by always
growing cultures with drug selection, and to passage cul-
tures before they were confluent.
Eleven of the thirty-eight cultures produced virus that
infected Vero cells and resulted in the generation of puro-
mycin-resistant colonies. Individual GFP-positive Vero co-
lonies that had grown under puromycin selection were
isolated using cloning rings, removed from the plate by
trypsin, transferred to a fresh 6-well plate, and expanded
with puromycin selection for further analysis. Vero cultures
with recombinant virus were tested for the production of
rKSHV.219 by induction with RTA expressed by BacK50
and sodium butyrate (as described below), and the amount of
rKSHV.219 present in cell-free media 3 days post induction
was determined by titering on 293 cells and counting GFP-
positive 2 days later (as described below). The four Vero
cultures that produced the highest level of virus were used
for hybridization analysis of the viral DNA. Two of these that
showed the correct pattern were subsequently used for
further experiments, including those presented here, and no
significant differences were seen between the two. The data
from one of these isolates is presented here.
Baculovirus
A recombinant baculovirus expressing the KSHV RTA
was constructed using the Bac-to-Bac Baculovirus (Invitro-
gen, Carlsbad, CA, USA) system. The KSHV/RTA con-
struct consisted of the DraI–SalI fragment, nucleotides71531–74815, with a deletion between the SacII sites
(nucleotides 71755–72316), placed under control of the
HCMV IE promoter. Virus was grown in SF9 cells in
Baculo Gold media, 10% FBS. Virus inoculum for mam-
malian cells was prepared from infected cultures by remov-
ing SF9 cells by centrifugation (400  g, 15 min) and
passed through a 0.8-AM filter, and stored at 4 jC. Infection
of mammalian cells was carried out for 2 h. Both RT and
37 jC were compared for baculovirus infection, and no
significant difference was seen.
It was found that both the concentration of BacK50 and
the amount used was critical to achieve high titers of
rKSHV.219 production, and the two-step procedure detailed
below was used to optimize BacK50 infections. Firstly, the
titer of baculovirus for the infection of mammalian cells was
determined by titering BacK50 stocks on Vero cells con-
taining rKSHV.219 and counting RFP-positive cells 2 days
post BacK50 infection. This was carried out by plating Vero
with rKSHV.219 in a 24-well plate (1.88 cm2) with 0.5 ml
of media. The cells were inoculated with 2-fold dilutions of
BacK50, where the 2-fold dilutions were started with 5 Al
and carried out for 12 dilutions. Titers from this procedure
should be 5  107 or higher to achieve optimal levels of
KSHV production. Lower titers of virus could not be
completely compensated for by just increasing the amount
baculovirus inoculum added. Secondly, the optimal amount
of BacK50 to use for maximal KSHV production was
determined by the infection of Vero cells (80–90% conflu-
ent) containing rKSHV.219 in a 12-well plate (3.83 cm2)
with BacK50 starting with 0.005 ml, and increasing by 0.01
ml increments to 0.2 ml per well. Following BacK50
infection, media with 1.25 mM sodium butyrate was added
and 3 days later the amount of rKSHV.219 produced was
determined on 293 cells as described below. Typically, a
multiplicity of infection of approximately 20–40 was found
appropriate, and the amount of BacK50 for any sized culture
vessel was extrapolated from the 3.83 cm2 well using the
number of cells, or the area of the culture vessel.
Production of rKSHV.219 and determination of infectious
units (IU)
For the generation of rKSHV.219 stocks, Vero cells
containing latent rKSHV.219 (80–90% confluent) were
infected with BacK50 for 2 h in a minimum volume, the
inoculum was removed, the cells washed once with PBS, and
fresh media with 1.25 mM sodium butyrate was added.
Twenty to thirty hours later, the media with sodium butyrate
was removed and fresh media, without puromycin, was
added. Any cells in the original media were collected by
centrifugation (300  g, 5 min) and returned to the flask. At
50–70 h post baculovirus infection, the media was collected,
cells were removed by centrifugation (300  g, 10 min), the
supernatant was passed through a 0.45- or 0.8-AM filter, and
was then used as KSHV inoculum. Infectious units (IU) of
rKSHV.219 were determined by titering virus present in cell-
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cells 2 days postinfection. Centrifugation enhancement was
used for infection by centrifuging the culture plate at 450 g
for 20 min, with replacement of media 2 h after centrifuga-
tion. This increased the infection level approximately 2- to 3-
fold over cultures infected without centrifugation.
Experiments examining virus production from the diffe-
rent cell types by the various activation processes were
carried out in 12-well plates with 3.83 cm2 wells. The
process was the same as for the production of stock virus
from Vero cultures described above, except the media with
sodium butyrate was left on the cultures for the entire time,
as it was found that this did not effect virus yield.
For all experiments, a representative result from one of at
least three experiments was used as data for graphs.
Infection of cells with rKSHV.219 and puromycin selection
rKSHV.219 produced from Vero cells was used to infect
human fibroblasts, 293 cells, MVEC, HaCaT, DU145, T24,
and Hep-2 were infected at a moi of approximately 1–5 as
determined by virus titer on 293 cells. Three days postin-
fection, cells were grown in media containing puromycin at
1 Ag/ml for 293, DU145, Hep2, and T24 cells, 0.5 Ag/ml for
HF, and 0.25 Ag/ml for MVEC.
Antibody detection of viral proteins
The IFA detection of KSHVORF 59 andORF 8.1 proteins
was carried out withMAb 11D1 (specific for ORF 59 protein)
(Chan et al., 1998), or MAbA4 (specific for ORF 8.1 protein)
(Zhu et al., 1999) diluted 1:10 in PBS–0.3% BSA as
previously described (Vieira et al., 2001), except Alexa 350
(Molecular Probes, Eugene, OR, USA) was used for fluores-
cent detection. For the IFA visualization of the latent nuclear
antigen (LANA), cells were fixed and reacted with rabbit
polyclonal antibody to LANA as previously described (Mo-
ses et al., 1999), except that the antibody was preabsorbed to
fixed and permeabilized cells not infected with KSHV for 30
min. For Vero cells, the polyclonal antibody to LANA was
followed with biotin-conjugated F(abV)2 fragment goat anti-
rabbit IgG (Jackson ImmunoResearch Inc., West Grove, PA,
USA) diluted 1:200 for 30 min at 37 jC. The samples were
washed twice with PBS and reacted with Alexa 594 strepta-
vidin for 10 min at 37 jC, and then washed twice with PBS,
and counterstained with 1 Ag/ml DAPI for 1 min and washed
in PBS. For 293 cells, the polyclonal LANA antibody was
followed by Alexa Fluor 633 F(abV)2 fragment of goat anti-
rabbit IgG (Molecular Probes) diluted 1:200 for 30 min,
washed twice with PBS, and counterstained with 1 Ag/ml
DAPI for 1 min and washed in PBS.
Hybridization analysis
DNA hybridization analysis was carried out on total
cellular DNA as previously described (Vieira et al., 2001)using the 4.8-kb BamHI fragment of KSHV DNA and the
puromycin resistance gene as probes labeled with 32P using
the Ready-To-Go labeling beads (Amersham, Piscataway,
NJ). Fifteen micrograms of total cellular DNA was used for
rKSHV.219 and 7 Ag of JSC-1 DNA was used for each
digest. The different amounts of DNAwere used to equalize
the amounts of viral DNA.
RNA hybridization analysis was carried out as described
(Goda and Minton, 1995) using 10 Ag of total cellular RNA
isolated with the RNA easy kit (Qiagen, Valencia, CA). The
K9 probe consisted of a BstXI fragment (83794–85745) and
the ORF 57 probe consisted of a Acc65I–DraIII fragment
(82342–83710), and were labeled with 32P using the
Ready-To-Go labeling beads (Amersham).
Microscopy
Nikon Eclipse TE300 inverted fluorescent microscope
equipped with filter sets TE300 FITC, TE300 Texas Red
HYQ, and TE300 633. Images were acquired with a Photo-
metrics CoolSnap cf digital camera and Metavue imaging
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